What happens to regulatory T cells in multiple myeloma

被引:0
|
作者
Chen, Huixian [1 ,2 ]
Wang, Xueling [1 ,3 ]
Wang, Yan [4 ]
Chang, Xiaotian [1 ]
机构
[1] Qingdao Univ, Affiliated Hosp, Med Res Ctr, Qingdao 266003, Peoples R China
[2] Qingdao Univ, Affiliated Hosp, Dept Hematol, Qingdao 266003, Peoples R China
[3] Qingdao Univ, Affiliated Hosp, Dept Gastroenterol, Qingdao 266003, Peoples R China
[4] Shandong Univ, Qilu Hosp, Dept Pediat, Jinan 250012, Peoples R China
关键词
TRANSCRIPTION FACTOR FOXP3; NATURAL-KILLER-CELL; PERIPHERAL-BLOOD; BONE-MARROW; SUPPRESSOR-CELLS; CD127; EXPRESSION; DENDRITIC CELLS; FUNCTIONAL-CHARACTERIZATION; INTERLEUKIN (IL)-2; ANTITUMOR IMMUNITY;
D O I
10.1038/s41420-023-01765-8
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Abnormal tumor microenvironment and immune escape in multiple myeloma (MM) are associated with regulatory T cells (Tregs), which play an important role in maintaining self-tolerance and regulating the overall immune response to infection or tumor cells. In patients with MM, there are abnormalities in the number, function and distribution of Tregs, and these abnormalities may be related to the disease stage, risk grade and prognosis of patients. During the treatment, Tregs have different responses to various treatment regiments, thus affecting the therapeutic effect of MM. It is also possible to predict the therapeutic response by observing the changes of Tregs. In addition to the above, we reviewed the application of Tregs in the treatment of MM. In conclusion, there is still much room for research on the mechanism and application of Tregs in MM.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications
    Yu-Tzu Tai
    Liang Lin
    Lijie Xing
    Shih-Feng Cho
    Tengteng Yu
    Chirag Acharya
    Kenneth Wen
    Phillip A. Hsieh
    John Dulos
    Andrea van Elsas
    Nikhil Munshi
    Paul Richardson
    Kenneth C. Anderson
    Leukemia, 2019, 33 : 426 - 438
  • [32] APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications
    Tai, Yu-Tzu
    Lin, Liang
    Xing, Lijie
    Cho, Shih-Feng
    Yu, Tengteng
    Acharya, Chirag
    Wen, Kenneth
    Hsieh, Phillip A.
    Dulos, John
    van Elsas, Andrea
    Munshi, Nikhil
    Richardson, Paul
    Anderson, Kenneth C.
    LEUKEMIA, 2019, 33 (02) : 426 - 438
  • [33] Prognostic role of the ratio of natural killer cells to regulatory T cells in patients with multiple myeloma treated with lenalidomide and dexamethasone
    Kim, Seung Yeon
    Park, Sung-Soo
    Lim, Ji-Young
    Lee, Jung Yeon
    Yoon, Jae-Ho
    Lee, Sung-Eun
    Eom, Ki-Seong
    Kim, Hee-Je
    Min, Chang-Ki
    EXPERIMENTAL HEMATOLOGY, 2022, 110 : 60 - 68
  • [34] What Happens Next (or Doesn't)
    Silver, Marisa
    NEW YORK TIMES BOOK REVIEW, 2017, 122 (09): : 15 - 15
  • [35] Multiple subsets of regulatory T-cells
    Kupriyanov, S., V
    Sinitsky, A., I
    Dolgushin, I. I.
    BYULLETEN SIBIRSKOY MEDITSINY, 2020, 19 (03): : 144 - 155
  • [36] The role of regulatory T cells in multiple sclerosis
    Zozulya, Alla L.
    Wiendl, Heinz
    NATURE CLINICAL PRACTICE NEUROLOGY, 2008, 4 (07): : 384 - 398
  • [37] The role of regulatory T cells in multiple sclerosis
    Alla L Zozulya
    Heinz Wiendl
    Nature Clinical Practice Neurology, 2008, 4 : 384 - 398
  • [38] Regulatory - What happens when an OSHA complaint is filed?
    Lechner, Wendy
    Instant and Small Commercial Printer, 2000, 19 (07):
  • [39] FREQUENCY OF CD4+CD25HIGH REGULATORY CELLS (T-REG CELLS) IN PATIENTS WITH MULTIPLE MYELOMA
    Bourantas, D.
    Xatzimichael, E.
    Fili, G.
    Baxevanos, G.
    Kolaitis, N.
    Vartholomatos, G.
    Bourantas, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 513 - 513
  • [40] Ex vivo evaluation of the effect of regulatory T cells on the anti-tumor activity of bortezomib in multiple myeloma
    Ercetin, Ayse Pinar
    Ozcan, Mehmet Ali
    Aktas, Safiye
    Yuksel, Faize
    Solmaz, Serife Medeni
    Sevindik, Gokmen Omur
    Katgi, Abdullah
    Piskin, Ozden
    Undar, Bulent
    EXPERIMENTAL HEMATOLOGY, 2016, 44 (04) : 223 - 230